A5064304983- Estrogen and related hormone effects
- Cytokine Signaling Pathways and Interactions
- Retinoids in leukemia and cellular processes
- Acute Lymphoblastic Leukemia research
- Colorectal Cancer Screening and Detection
- Acute Myeloid Leukemia Research
- Nuclear Receptors and Signaling
- Childhood Cancer Survivors' Quality of Life
- Genetic factors in colorectal cancer
- Neutropenia and Cancer Infections
- Chemokine receptors and signaling
- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Otitis Media and Relapsing Polychondritis
- Hematological disorders and diagnostics
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Advancements in Semiconductor Devices and Circuit Design
- Adrenal and Paraganglionic Tumors
- Chronic Myeloid Leukemia Treatments
- Inflammatory mediators and NSAID effects
- Cancer survivorship and care
- Neuroblastoma Research and Treatments
- Breast Cancer Treatment Studies
- Eicosanoids and Hypertension Pharmacology
National Comprehensive Cancer Network
2017-2021
Pancreatic Cancer Action Network
2018-2021
University of Colorado Anschutz Medical Campus
2013-2014
Case Western Reserve University
2005-2013
Boston Children's Hospital
2010
Institute of Pharmacology
2008
Benedict College
2005
Acute myeloid leukemia (AML) is the most common form of acute among adults and accounts for largest number annual deaths due to leukemias in United States. This portion NCCN Guidelines AML focuses on management provides recommendations workup, diagnostic evaluation, treatment options younger (age <60 years) older ≥60 adult patients.
Acute myeloid leukemia (AML) is the most common form of acute among adults and accounts for largest number annual deaths due to leukemias in United States. Recent advances have resulted an expansion treatment options AML, especially concerning targeted therapies low-intensity regimens. This portion NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) AML focuses on management provides recommendations workup, diagnostic evaluation younger (age <60 years) older ≥60 adult patients.
The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, paragangliomas. Management NETs relies heavily on site primary NET. These Insights summarize options 2018 updates to guidelines locoregional advanced disease, and/or distant metastasis originating from gastrointestinal tract, bronchopulmonary, thymus NETs.
Identifying individuals with hereditary syndromes allows for improved cancer surveillance, risk reduction, and optimized management. Establishing criteria assessment the identification of who are carriers pathogenic genetic variants. The NCCN Guidelines Genetic/Familial High-Risk Assessment: Colorectal provide recommendations management patients high-risk colorectal syndromes. These Insights focus on evaluation Lynch syndrome considerations use multigene testing in
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or yielded new information regarding factors prognostic importance, are intended aid physicians decision-making. These Insights focus recent select updates Guidelines, including familial genetic alterations AML, postinduction postremission strategies low-risk acute promyelocytic leukemia...
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal provide recommendations the management of patients with high-risk syndromes associated an increased risk colorectal cancer (CRC). Panel meets at least annually to assess comments from reviewers within their institutions, examine relevant data, and reevaluate update recommendations. These Insights focus on genes newly CRC multigene panels, evidence, currently recommended strategies.
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of biology disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management needed improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) who experience relapse. The NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) ALL provide...
The NCCN Guidelines for Colorectal Cancer (CRC) Screening outline various screening modalities as well recommended strategies individuals at average or increased-risk of developing sporadic CRC. panel meets least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate update recommendations. These Insights summarize 2018 updates the Guidelines, with a primary focus on used screen average-risk
This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on management classical HL. Current HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging PET/CT to assess response using Deauville criteria (5-point scale). The introduction less toxic and more effective regimens has significantly advanced cure rates. However, long-term follow-up after completion is essential determine potential effects.
The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations the management of adult patients with HL. panel meets at least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate update recommendations. Current classic HL involves initial treatment chemotherapy alone or combined modality therapy followed by restaging PET/CT assess response. Overall, introduction less toxic more effective regimens has...
The NCCN Guidelines for Colorectal Cancer (CRC) Screening describe various colorectal screening modalities as well recommended schedules patients at average or increased risk of developing sporadic CRC. They are intended to aid physicians with clinical decision-making regarding CRC without defined genetic syndromes. These Insights focus on select recent updates the Guidelines, including a section primary and secondary prevention, provide context panel’s recommendations age initiate in...
The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, management relapsed or refractory (R/R) ALL remains challenging is poor. NCCN Guidelines provide recommendations on standard treatment approaches based current evidence. These Insights summarize R/R highlight important updates, a summary panel's...
Palliative care has evolved to be an integral part of comprehensive cancer with the goal early intervention improve quality life and patient outcomes. The NCCN Guidelines for Care provide recommendations help primary oncology team promote best possible throughout illness trajectory each cancer. Panel meets annually evaluate update based on panel members' clinical expertise emerging scientific data. These Insights summarize panel's recent discussions highlights updates importance fostering...
Abstract Introduction Luminal, estrogen receptor-positive (ER + ) breast cancers can metastasize but lie dormant for years before recurrences prove lethal. Understanding the roles of (E) or progestin (P) in development luminal metastases arousal from dormancy is hindered by few preclinical models. We have developed such Methods Immunocompromised, ovariectomized (ovx’d) mice were intracardiac-injected with basal human cancer cells. Four lines tested: ER PR cytokeratin 5-negative (CK5 − E3 and...
The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations the management of adult patients with HL. Panel meets at least annually to review comments from reviewers within Member Institutions, examine relevant data, and reevaluate update recommendations. These Insights summarize recent updates centered on treatment considerations relapsed/refractory classic
Estrogen receptor alpha (ERalpha) plays a key role in mammary gland development and is implicated breast cancer through the transcriptional regulation of genes linked to proliferation apoptosis. We previously reported that hexamethylene bisacetamide inducible protein 1 (HEXIM1) inhibits activity ligand-bound ERalpha bridges functional interaction between positive transcription elongation factor b (P-TEFb). To examine consequences HEXIM1-ERalpha-P-TEFb vivo, we generated MMTV/HEXIM1 mice...
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia non-Hodgkin's lymphoma is setting the stage what possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, costs associated CAR therapy. To begin to address these issues, NCCN...
We have previously reported on the inhibition of HIF-1α (hypoxia-inducible factor α)-regulated pathways by HEXIM1 [HMBA (hexamethylene-bis-acetamide)-inducible protein 1]. Disruption activity in a knock-in mouse model expressing mutant resulted increased susceptibility to development mammary tumours, partly up-regulation VEGF (vascular endothelial growth factor) expression, expression and aberrant vascularization. now report mechanistic basis for regulation HIF-1α. observed direct...
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental contaminants, which suspected carcinogens and may affect the reproductive system as potential endocrine disruptors. Therefore, we tested fluoranthene (FL) benzo[a]pyrene (BaP) on human breast cancer cell line (MCF–7 cells) to determine possible toxic effects. The cells were incubated in presence of medium, medium containing 0.1% dimethylsulfoxide (DMSO) vehicle, or FL (10, 50, 100 μ g/ml), BaP 17β –estradiol (E2; 5 g/ml 500...
Abstract Luminal, estrogen (ER) and/or progesterone (PR) receptor-positive breast cancers are the least aggressive forms of disease. However, luminal most common (70-80%) cancer subtype and therefore overall responsible for greatest number deaths due to metastases. The role estrogens (E) in promoting growth is well known. In contrast, little known about E or (P) metastasis. Most metastasis models use ER-PR- basal-like cells which women's hormones cannot be studied. We have generated a model...
Supplementary Figures 1-4 from HEXIM1 Regulates 17β-Estradiol/Estrogen Receptor-α–Mediated Expression of Cyclin D1 in Mammary Cells via Modulation P-TEFb